- Home
- SEAT vs PROK Comparison
SEAT vs PROK Comparison
Compare SEAT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- PROK
- Stock Information
- Founded
- SEAT 2001
- PROK 2015
- Country
- SEAT United States
- PROK United States
- Employees
- SEAT N/A
- PROK N/A
- Industry
- SEAT Industrial Machinery/Components
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEAT Industrials
- PROK Health Care
- Exchange
- SEAT Nasdaq
- PROK Nasdaq
- Market Cap
- SEAT 366.2M
- PROK 384.2M
- IPO Year
- SEAT N/A
- PROK N/A
- Fundamental
- Price
- SEAT $16.81
- PROK $2.52
- Analyst Decision
- SEAT Buy
- PROK Buy
- Analyst Count
- SEAT 11
- PROK 5
- Target Price
- SEAT $68.00
- PROK $6.25
- AVG Volume (30 Days)
- SEAT 282.5K
- PROK 2.4M
- Earning Date
- SEAT 08-05-2025
- PROK 08-12-2025
- Dividend Yield
- SEAT N/A
- PROK N/A
- EPS Growth
- SEAT N/A
- PROK N/A
- EPS
- SEAT N/A
- PROK N/A
- Revenue
- SEAT $694,007,000.00
- PROK $527,000.00
- Revenue This Year
- SEAT N/A
- PROK $265.05
- Revenue Next Year
- SEAT N/A
- PROK N/A
- P/E Ratio
- SEAT N/A
- PROK N/A
- Revenue Growth
- SEAT N/A
- PROK N/A
- 52 Week Low
- SEAT $15.13
- PROK $0.46
- 52 Week High
- SEAT $100.00
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- SEAT 34.43
- PROK 49.64
- Support Level
- SEAT $16.61
- PROK $2.30
- Resistance Level
- SEAT $17.40
- PROK $2.53
- Average True Range (ATR)
- SEAT 0.98
- PROK 0.19
- MACD
- SEAT 0.53
- PROK -0.02
- Stochastic Oscillator
- SEAT 64.70
- PROK 74.44
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.